FDA Extends Review Period for Exelixis' Zanzalinib
EXEL Exelixis Inc
$64.53 -1.19%
View chart & analysis → - 1The U.S. Food and Drug Administration has decided to extend the review period for Exelixis' zanzalinib.
- 2The expected decision date has been pushed back from December 3, 2026, to March 3, 2027.
- 3Exelixis shares have risen 49% this year, outperforming market returns.
So what's the key point?
The U.S. Food and Drug Administration has decided to take more time to review a drug from Exelixis. The date for the final decision has been moved to March 3, 2027.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.